 |
|
|
| |
POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR
IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH
|
| |
| |
CROI 2021 March 6-10 Reported by Jules Levin
Sorana Segal-Maurer , Antonella Castagna , Mezgebe Berhe , Gary Richmond , Peter J. Ruane , Gary I. Sinclair , Krittaecho Siripassorn , Ya-Pei Liu , Nicolas Margot , Hadas Dvory-Sobol , Robert H. Hyland , Martin Rhee , Jared Baeten, Diana Brainard , Edwin DeJesus
1New York-Presbyterian Queens, Flushing, NY, USA, 2Ospedale San Raffaele, Milano, Italy, 3Texas Infectious Diseases Consultants, Dallas, TX, USA, 4Gary J Richmond, MD, PA, Fort Lauderdale, FL, USA, 5Ruane Clinical Research Group, Los Angeles, CA, USA, 6Prism Health North Texas, Dallas, TX, USA, 7Bamrasnaradura Infectious Diseases Institute, Bangkok, Thailand, 8Gilead Sciences, Inc, Foster City, CA, USA, 9Orlando Immunology Center, Orlando, FL, USA
CROI: Gilead's Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI - (03/10/21)
|
| |
|
|
|
|
|
